Insmed Incorporated

INSM

Held by 6 specialist biotech funds

High Convergence

Share on X

Fund Holdings

6 fund convergence

Baker Bros. Advisors Driehaus Capital OrbiMed Advisors

Position Trend

Feb 13, 2026

$84.2M

1 fund

Feb 17, 2026

$2068.6M

5 funds

+2358% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 6,592,746Value: $1147.4M

**Signal Note: Baker Bros. Initiates ~$1.15B Position in Insmed (INSM)** Baker Bros.' new concentrated position in Insmed is a high-conviction bet almost certainly centered on brensocatib, a DPP1 inhibitor that delivered strong Phase 3 ASPEN results in bronchiectasis (reducing exacerbations ~21%) and is under FDA review with a PDUFA target date of August 2, 2025. The position size — over $1.1B — is extraordinary even for Baker Bros. and suggests confidence in both approval and commercial potential in a disease with no approved therapies in the US, representing a multi-billion-dollar market opportunity. Key near-term catalysts include the PDUFA decision and potential EU filing, with any Advisory Committee meeting (if scheduled) serving as an interim inflection point.

Driehaus CapitalNEW

More INSM Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS3 funds NBIX3 funds IRON3 funds PRAX3 funds EWTX3 funds ELVN3 funds SYRE3 funds PHVS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Initiates $18.4M Position in INSM Driehaus Capital's new $18.4M stake in Insmed signals conviction in the company's lead asset Arikayce (amikacin liposome inhalation suspension), an inhaled antibiotic approved for nontuberculous mycobacterial (NTM) lung infections with a validated orphan disease market. The timing likely reflects confidence in Arikayce's commercial ramp and potential label expansion catalysts, including the ongoing Phase 3 trial in CF-related mycobacterial infections and European regulatory progress. For a growth-focused manager, this entry suggests belief in INSM's ability to achieve meaningful revenue inflection from a large but underserved patient population.